|
|
|
|
Alexion Pharmaceuticals may have a bigger market for its drug Soliris
It is still a one-hit wonder, dependent upon a single drug that treats a rare illness.But Alexion Pharmaceuticals, the Connecticut drug maker building its first production plant in Smithfield, may soon have a bigger audience for the sole...
|
|
|
Johns Hopkins researchers edit genes in human stem cells
Researchers at the Johns Hopkins School of Medicine have successfully edited the genome of human- induced pluripotent stem cells, making possible the future development of patient-specific stem cell therapies.Reporting this week in Cell...
|
|
|
Researchers Edit Genes in Human Stem Cells
Newswise Researchers at the Johns Hopkins School of Medicine have successfully edited the genome of human- induced pluripotent stem cells, making possible the future development of patient-specific stem cell therapies.Reporting this week...
|
|
|
Intraoperative Autologous Transfusion of Hemolyzed Blood
(Click the title below to leave the MDLinx Network and go to the Journal's Website) Anesthesia & Analgesia, 06/19/09 Print Save in My Library Free Abstract Sloan TB et al.- During two cases of lumbar spine surgery with...
|
|
|
Johns Hopkins Researchers Edit Genes in Human Stem Cells- 6/18/09
Researchers at the Johns Hopkins School of Medicine have successfully edited the genome of human- induced pluripotent stem cells, making possible the future development of patient-specific stem cell therapies.Reporting this week in Cell...
|
|
|
Johns Hopkins researchers edit genes in human stem cells
- Researchers at the Johns Hopkins School of Medicine have successfully edited the genome of human- induced pluripotent stem cells, making possible the future development of patient-specific stem cell therapies.Reporting in Cell Stem Cell...
|
|
|
Johns Hopkins Researchers Edit Genes in Human Stem Cells
BALTIMORE, June 18 (AScribe Newswire) -- Researchers at the Johns Hopkins School of Medicine have successfully edited the genome of human-induced pluripotent stem cells, making possible the future development of patient-specific stem cell...
|
|
|
Researchers Edit Genes In Human Stem Cells
Researchers at the Johns Hopkins School of Medicine have successfully edited the genome of human- induced pluripotent stem cells, making possible the future development of patient-specific stem cell therapies.Reporting this week in Cell...
|
|
|
Scientists edit genes in human stem cells
Researchers at the Johns Hopkins School of Medicine have successfully edited the genome of human- induced pluripotent stem cells, making possible the future development of patient-specific stem cell therapies.Reporting this week in Cell...
|
|
|
Researchers Edit Genes In Human Stem Cells
Researchers at the Johns Hopkins School of Medicine have successfully edited the genome of human- induced pluripotent stem cells, making possible the future development of patient-specific stem cell therapies.Reporting this week in , the...
|
|
|
Genes Edited In Human Stem Cells
Researchers at the Johns Hopkins School of Medicine have successfully edited the genome of human- induced pluripotent stem cells, making possible the future development of patient-specific stem cell therapies.Reporting in Cell Stem Cell,...
|
|
|
Researchers edit genes in human stem cells
Researchers at the Johns Hopkins School of Medicine have successfully edited the genome of human- induced pluripotent stem cells, making possible the future development of patient-specific stem cell therapies.Reporting this week in Cell...
|
|
|
Johns Hopkins researchers edit genes in human stem cells
Researchers at the Johns Hopkins School of Medicine have successfully edited the genome of human- induced pluripotent stem cells, making possible the future development of patient-specific stem cell therapies.Reporting this week in Cell...
|
|
|
Alexion's Soliris Wins Prix Galien Award
Alexion Pharmaceutical France and Alexion Pharmaceuticals have been awarded the 2009 Prix Galien France for its Soliris treatment in the rare diseases category.The award recognises the complement-inhibition technology of Soliris as an...
|
|
|
Alexion's Soliris(R) Receives 2009 Prix Galien France For Most Innovative Drug For Rare Disease
Alexion Pharma France and Alexion Pharmaceuticals, Inc.(NASDAQ: ALXN) today received the 2009 Prix Galien France for Soliris (eculizumab) in the category of medicines for rare diseases. The award recognizes the scientific innovation...
|
|
|
Alexion's Soliris Receives 2009 Prix Galien France for Most Innovative Drug for Rare Disease
- Alexion Pharma France and Alexion Pharmaceuticals, Inc.(NASDAQ: ALXN) today received the 2009 Prix Galien France for Soliris (eculizumab) in the category of medicines for rare diseases. The award recognizes the scientific innovation...
|
|
|
Alexion's Soliris Receives 2009 Prix Galien France for Most Innovative Drug for Rare Disease
- Alexion Pharma France and Alexion Pharmaceuticals, Inc.(NASDAQ: ALXN) today received the 2009 Prix Galien France for Soliris (eculizumab) in the category of medicines for rare diseases. The award recognizes the scientific innovation...
|
|
|
Cheshire firms Soliris drug lauded (posted Today at 11:13am)
Leerink Swann analyst Howard Liang reaffirmed an 'outperform' rating for Cheshire-based Alexion Pharmaceuticals Inc.today, citing the future revenue potential for its key drug Soliris. Soliris, Alexion's only marketed product, treats a...
|
|
|
New Research Presented at EHA Congress Shows That Soliris Significantly Reduced Hemolysis in Never-Transfuse
- Clinical investigators observed that Soliris (eculizumab), a first-in-class terminal complement inhibitor developed by Alexion Pharmaceuticals, Inc.(Nasdaq: ALXN), reduced hemolysis (red blood cell destruction) and improved symptoms in...
|
|
|
New Research Presented At EHA Congress Shows That Soliris(R) Significantly Reduced Hemolysis In Never-Transfus
Clinical investigators observed that Soliris (eculizumab), a first-in-class terminal complement inhibitor developed by Alexion Pharmaceuticals, Inc.(Nasdaq: ALXN), reduced hemolysis (red blood cell destruction) and improved symptoms in...
|
|
|
Leerink Swann analyst sees more potential for Alexion Pharmaceuticals' Soliris
NEW YORK (AP) - Leerink Swann analyst Howard Liang reaffirmed an 'Outperform' rating for Alexion Pharmaceuticals Inc.Tuesday, citing the future revenue potential for its key drug Soliris. Soliris, the company's only marketed product,...
|
|
|
Ahead of the Bell: Alexion Pharmaceuticals
NEW YORK - Leerink Swann analyst Howard Liang reaffirmed an 'Outperform' rating for Alexion Pharmaceuticals Inc.Tuesday, citing the future revenue potential for its key drug Soliris. Soliris, the company's only marketed product, treats...
|
|
|
Ahead of the Bell: Alexion Pharmaceuticals
NEW YORK (AP) -- Leerink Swann analyst Howard Liang reaffirmed an 'Outperform' rating for Alexion Pharmaceuticals Inc.Tuesday, citing the future revenue potential for its key drug Soliris. Soliris, the company's only marketed product,...
|
|
|
Alexion Pharma's (ALXN) Soliris(R) Receives Positive Opinion from Clinical Investigators
Clinical investigators observed that Soliris(R) (eculizumab), a first-in-class terminal complement inhibitor developed by Alexion Pharmaceuticals, Inc.(Nasdaq: ALXN), reduced hemolysis (red blood cell destruction) and improved symptoms in...
|
|
|
New Research Presented at EHA Congress Shows That Soliris Significantly Reduced Hemolysis in Never-Transfused
CHESHIRE, Conn.- (BUSINESS WIRE) - Clinical investigators observed that Soliris (eculizumab), a first-in-class terminal complement inhibitor developed by Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN), reduced hemolysis (red blood cell...
|
